Indirect comparison of efficacy of zanubrutinib versus acalabrutinib in the treatment of relapsed/refractory mantle cell lymphoma
Zanubrutinib vs. acalabrutinib in B-cell malignancies: An adverse event-based economic analysis
Zanubrutinib (zanu) versus acalabrutinib (acala) in B-cell malignancies: an adverse event (AE)-based economic analysis
Targeted Literature Review of Cost-Effectiveness Models in Relpased/Refractory Folicular Lymphoma
Navigating Economics of Telehealth in Oncology
HRT and breast cancer – Fast facts. Post-Reproductive Health
Risks and benefits of hormone replacement therapy before and after a breast cancer diagnosis
Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden
Understanding Breast Cancer Patient Pathways and their impact on Survival in Mexico
Epidemiology, Treatment Patterns, Humanistic And Economic Burden Of Biliary Tract Carcinoma: A Systematic And Targeted Literature Review
